Lineage Cell Therapeutics, Inc.: total equity including noncontrolling interests

What this measure means

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Exact concept: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2008-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.

Selected filing history

Related financial histories

• Lineage Cell Therapeutics, Inc.: total assets
• Lineage Cell Therapeutics, Inc.: total liabilities
• Lineage Cell Therapeutics, Inc.: stockholders equity
• Lineage Cell Therapeutics, Inc.: cash and cash equivalents
• Lineage Cell Therapeutics, Inc.: net income or loss
• Lineage Cell Therapeutics, Inc.: operating cash flow
• Lineage Cell Therapeutics, Inc.: capital expenditure payments
• Lineage Cell Therapeutics, Inc.: revenue
• Lineage Cell Therapeutics, Inc.: contract revenue excluding tax
• Lineage Cell Therapeutics, Inc.: financing cash flow
• Lineage Cell Therapeutics, Inc.: investing cash flow
• Lineage Cell Therapeutics, Inc.: retained earnings or deficit
• Lineage Cell Therapeutics, Inc.: basic weighted-average shares
• Lineage Cell Therapeutics, Inc.: diluted weighted-average shares
• Lineage Cell Therapeutics, Inc.: basic earnings per share
• Lineage Cell Therapeutics, Inc.: diluted earnings per share
• Lineage Cell Therapeutics, Inc.: income tax expense or benefit
• Lineage Cell Therapeutics, Inc.: net property, plant and equipment
• Lineage Cell Therapeutics, Inc.: share-based compensation expense
• Lineage Cell Therapeutics, Inc.: operating income or loss
• Lineage Cell Therapeutics, Inc.: current assets
• Lineage Cell Therapeutics, Inc.: current liabilities
• Lineage Cell Therapeutics, Inc.: current accounts payable
• Lineage Cell Therapeutics, Inc.: net finite-lived intangible assets
• Lineage Cell Therapeutics, Inc.: net current accounts receivable
• Lineage Cell Therapeutics, Inc.: operating expenses
• Lineage Cell Therapeutics, Inc.: net inventory
• Lineage Cell Therapeutics, Inc.: gross profit
• Lineage Cell Therapeutics, Inc.: cost of revenue
• Lineage Cell Therapeutics, Inc.: research and development expense
• Lineage Cell Therapeutics, Inc.: common shares outstanding
• Lineage Cell Therapeutics, Inc.: cash including restricted cash
• Lineage Cell Therapeutics, Inc.: additional paid-in capital
• Lineage Cell Therapeutics, Inc.: accumulated other comprehensive income or loss
• Lineage Cell Therapeutics, Inc.: operating lease right-of-use asset
• Lineage Cell Therapeutics, Inc.: operating lease liability
• Lineage Cell Therapeutics, Inc.: gross property, plant and equipment
• Lineage Cell Therapeutics, Inc.: accumulated depreciation on property, plant and equipment
• Lineage Cell Therapeutics, Inc.: net intangible assets excluding goodwill
• Lineage Cell Therapeutics, Inc.: other noncurrent liabilities
• Lineage Cell Therapeutics, Inc.: accrued current liabilities
• Lineage Cell Therapeutics, Inc.: prepaid expenses and other current assets
• Lineage Cell Therapeutics, Inc.: current contract liabilities
• Lineage Cell Therapeutics, Inc.: net deferred tax assets
• Lineage Cell Therapeutics, Inc.: net deferred tax liabilities
• Lineage Cell Therapeutics, Inc.: pre-tax income or loss from continuing operations
• Lineage Cell Therapeutics, Inc.: profit or loss including noncontrolling interests
• Lineage Cell Therapeutics, Inc.: comprehensive income or loss
• Lineage Cell Therapeutics, Inc.: net income available to common stockholders
• Lineage Cell Therapeutics, Inc.: general and administrative expense
• Lineage Cell Therapeutics, Inc.: depreciation expense
• Lineage Cell Therapeutics, Inc.: depreciation, depletion and amortization
• Lineage Cell Therapeutics, Inc.: amortization of intangible assets
• Lineage Cell Therapeutics, Inc.: other nonoperating income or expense
• Lineage Cell Therapeutics, Inc.: nonoperating income or expense
• Lineage Cell Therapeutics, Inc.: deferred income tax expense or benefit
• Lineage Cell Therapeutics, Inc.: interest paid, net
• Lineage Cell Therapeutics, Inc.: proceeds from issuing common stock
• Lineage Cell Therapeutics, Inc.: operating lease payments
• Lineage Cell Therapeutics, Inc.: change in accounts receivable
• Lineage Cell Therapeutics, Inc.: change in inventories

Inspect the source

Entity

Lineage Cell Therapeutics, Inc. / CIK 0000876343

Captured

2026-09-20T05:01:04.503Z

SEC response SHA-256

de850ac42665e48058d541d948514740e0c9007b61646401dcae831c504c80bf

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000876343.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))